AstraZeneca (NASDAQ: AZN) and its co-development partner, Japan’s Daiichi Sankyo, have released data from the TROPION-Lung01 Phase III study, which focuses on the TROP-2-targeted antibody drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd) as a second-line treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC). The molecule did not achieve the primary endpoint of overall survival (OS) in the overall population but showed clinical benefits for the non-squamous patient sub-group.
Dato-DXd was compared to docetaxel, with the former achieving a numerically improved overall survival (OS) of 12.9 months versus 11.8 months. In the non-squamous population, Dato-DXd demonstrated a 2.3-month improvement in OS compared to docetaxel, at 14.6 months versus 12.3 months. Previously, in 2024, AstraZeneca published data showing clinically significant progression-free survival (PFS) in both the overall population and non-squamous subset in the same TROPION-Lung01 study. The full data from the study is being presented at the IASLC 2024 World Conference on Lung Cancer and simultaneously published in the Journal of Clinical Oncology . – Flcube.com
